CL2013002219A1 - Composicion inmunogena que comprende bordetella bronchiseptica y un antigeno de pertactina aislado; y su uso para tratar o prevenir la infeccion por un patogeno respiratorio canino en un perro. - Google Patents
Composicion inmunogena que comprende bordetella bronchiseptica y un antigeno de pertactina aislado; y su uso para tratar o prevenir la infeccion por un patogeno respiratorio canino en un perro.Info
- Publication number
- CL2013002219A1 CL2013002219A1 CL2013002219A CL2013002219A CL2013002219A1 CL 2013002219 A1 CL2013002219 A1 CL 2013002219A1 CL 2013002219 A CL2013002219 A CL 2013002219A CL 2013002219 A CL2013002219 A CL 2013002219A CL 2013002219 A1 CL2013002219 A1 CL 2013002219A1
- Authority
- CL
- Chile
- Prior art keywords
- dog
- treat
- bordetella bronchiseptica
- immunogenic composition
- respiratory pathogen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/098—Brucella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
UNA COMPOSICIÓN INMUNÓGENA QUE COMPRENDE BORDETELLA BRONCHISEPTICA Y UN ANTÍGENO DE PERTACTINA AISLADO. UNA COMPOSICIÓN INMUNÓGENA QUE COMPRENDE UNA PLURALIDAD DE ANTÍGENOS DE PERTACTINA P68 RECOMBINANTES DONDE DICHA COMPOSICIÓN ESTÁ SUSTANCIALMENTE LIBRE DE AGREGADOS DE P68. USO DE DICHA COMPOSICIÓN INMUNÓGENA PORQUE SIRVE PARA PREPARAR UN MEDICAMENTO ÚTIL EN EL TRATAMIENTO O LA PREVENCIÓN DE LA INFECCIÓN POR UN PATÓGENO RESPIRATORIO CANINO EN UN PERRO.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161439597P | 2011-02-04 | 2011-02-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2013002219A1 true CL2013002219A1 (es) | 2014-01-31 |
Family
ID=45755432
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2013002219A CL2013002219A1 (es) | 2011-02-04 | 2013-08-02 | Composicion inmunogena que comprende bordetella bronchiseptica y un antigeno de pertactina aislado; y su uso para tratar o prevenir la infeccion por un patogeno respiratorio canino en un perro. |
Country Status (26)
Country | Link |
---|---|
US (1) | US20130302369A1 (es) |
EP (2) | EP2670432B1 (es) |
JP (1) | JP5833145B2 (es) |
KR (1) | KR101647180B1 (es) |
CN (2) | CN107296955B (es) |
AU (2) | AU2012213035A1 (es) |
BR (1) | BR112013019675B8 (es) |
CA (1) | CA2826060C (es) |
CL (1) | CL2013002219A1 (es) |
CO (1) | CO6791568A2 (es) |
CY (1) | CY1124093T1 (es) |
DK (1) | DK2670432T3 (es) |
ES (1) | ES2869175T3 (es) |
HK (1) | HK1245676A1 (es) |
HR (1) | HRP20210575T1 (es) |
HU (1) | HUE055669T2 (es) |
LT (1) | LT2670432T (es) |
MX (1) | MX347177B (es) |
PL (1) | PL2670432T3 (es) |
PT (1) | PT2670432T (es) |
RS (1) | RS61723B1 (es) |
RU (1) | RU2554480C2 (es) |
SI (1) | SI2670432T1 (es) |
UA (2) | UA110504C2 (es) |
WO (1) | WO2012104821A1 (es) |
ZA (1) | ZA201306615B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3311827T3 (da) | 2011-10-03 | 2023-04-03 | Canqura Oncology Ab | Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærere for amfipatiske eller hydrofobe molekyler inden for det medicinske område, inklusiv cancerbehandling, samt fødevarerelaterede forbindelser |
MX363510B (es) * | 2012-05-31 | 2019-03-26 | Zoetis Llc | Vacuna con coronavirus respiratorio canino para proteccion contra infecciones de b. bronchiseptica. |
CA2924526A1 (en) * | 2013-09-19 | 2015-03-26 | Paul Joseph Dominowski | Water-in-oil emulsions comprising immunostimulatory oligonucleotides |
EP4241853A3 (en) * | 2013-11-26 | 2023-11-22 | Zoetis Services LLC | Compositions for induction of immune response |
PL3244920T3 (pl) | 2015-01-16 | 2023-09-25 | Zoetis Services Llc | Szczepionka przeciw pryszczycy |
EP3909971A1 (en) | 2020-09-28 | 2021-11-17 | Institute of Life Sciences (ILS) | Whole cell livestock vaccine for respiratory diseases |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2571618A1 (fr) | 1984-10-12 | 1986-04-18 | Virbac Ctre Rech Biolog | Nouveau vaccin contre la tracheobronchite infectieuse canine et son procede de preparation |
US5019388A (en) * | 1986-10-14 | 1991-05-28 | Norden Laboratories Inc. | Bordetella bronchiseptica vaccine |
US4888169A (en) * | 1986-10-14 | 1989-12-19 | Norden Laboratories, Inc. | Bordetella Bronchiseptica vaccine |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
DE69735856T2 (de) * | 1996-05-31 | 2006-11-16 | National University Of Ireland Maynooth, Maynooth | Il-12 als adjuvanz für bordetella pertussis impfstoffe |
SK283565B6 (sk) * | 1996-07-02 | 2003-09-11 | Connaught Laboratories Limited | Multivalentná imunogénna kompozícia a jej použitie |
ATE393166T1 (de) * | 2000-05-25 | 2008-05-15 | Pasteur Institut | Polypeptide die polymorphismen aus bordertella pertussis, bordetella parapertussis und bordetella bronchiseptica pertactin wiederholende regionen enthalten, ihre verwendung in diagnostik und immunogene zusammensetzungen |
GB0217434D0 (en) * | 2002-07-27 | 2002-09-04 | Royal Vetinary College | Biological material |
US20050089533A1 (en) * | 2003-01-29 | 2005-04-28 | Joseph Frantz | Canine vaccines against Bordetella bronchiseptica |
JP2006515024A (ja) * | 2003-01-29 | 2006-05-18 | ファイザー・プロダクツ・インク | Bordetellabronchisepticaに対するイヌワクチン |
GB0315323D0 (en) | 2003-07-01 | 2003-08-06 | Royal Veterinary College | Vaccine composition |
US8574596B2 (en) * | 2003-10-02 | 2013-11-05 | Glaxosmithkline Biologicals, S.A. | Pertussis antigens and use thereof in vaccination |
US7572620B2 (en) | 2005-01-11 | 2009-08-11 | Wisconsin Alumni Research Foundation | H3 equine influenza A virus |
CA2604488A1 (en) * | 2005-04-07 | 2006-10-12 | Pharmacia & Upjohn Company Llc | Formulations and process for production of bordetella bronchiseptica p68 antigen and vaccines |
US7959929B2 (en) | 2005-04-21 | 2011-06-14 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
US7384642B2 (en) | 2005-08-25 | 2008-06-10 | Merial Limited | Canine influenza vaccines |
KR20110126726A (ko) * | 2005-10-07 | 2011-11-23 | 화이자 프로덕츠 인코포레이티드 | 개과 동물의 인플루엔자의 치료를 위한 백신 및 방법 |
US7468187B2 (en) | 2005-10-18 | 2008-12-23 | Iowa State University Research Foundation, Inc. | Canine influenza virus and related compositions and methods of use |
WO2007047728A2 (en) * | 2005-10-20 | 2007-04-26 | Wyeth | Compositions and methods for the treatment of canine influenza virus disease |
US7682619B2 (en) * | 2006-04-06 | 2010-03-23 | Cornell Research Foundation, Inc. | Canine influenza virus |
AU2007252296A1 (en) * | 2006-05-19 | 2007-11-29 | The Walter And Eliza Hall Institute Of Medical Research | Immunogenic compositions |
-
2012
- 2012-02-03 LT LTEP12705438.5T patent/LT2670432T/lt unknown
- 2012-02-03 CN CN201710294793.6A patent/CN107296955B/zh active Active
- 2012-02-03 PT PT127054385T patent/PT2670432T/pt unknown
- 2012-02-03 SI SI201231911T patent/SI2670432T1/sl unknown
- 2012-02-03 RS RS20210474A patent/RS61723B1/sr unknown
- 2012-02-03 CN CN201280015807.1A patent/CN103561763A/zh active Pending
- 2012-02-03 US US13/983,127 patent/US20130302369A1/en active Pending
- 2012-02-03 DK DK12705438.5T patent/DK2670432T3/da active
- 2012-02-03 AU AU2012213035A patent/AU2012213035A1/en not_active Abandoned
- 2012-02-03 KR KR1020137022854A patent/KR101647180B1/ko active IP Right Grant
- 2012-02-03 CA CA2826060A patent/CA2826060C/en active Active
- 2012-02-03 PL PL12705438T patent/PL2670432T3/pl unknown
- 2012-02-03 MX MX2013009012A patent/MX347177B/es active IP Right Grant
- 2012-02-03 ES ES12705438T patent/ES2869175T3/es active Active
- 2012-02-03 EP EP12705438.5A patent/EP2670432B1/en active Active
- 2012-02-03 BR BR112013019675A patent/BR112013019675B8/pt active IP Right Grant
- 2012-02-03 JP JP2013552317A patent/JP5833145B2/ja active Active
- 2012-02-03 EP EP21162470.5A patent/EP3858381A1/en active Pending
- 2012-02-03 RU RU2013136151/10A patent/RU2554480C2/ru active
- 2012-02-03 HU HUE12705438A patent/HUE055669T2/hu unknown
- 2012-02-03 WO PCT/IB2012/050512 patent/WO2012104821A1/en active Application Filing
- 2012-03-02 UA UAA201309552A patent/UA110504C2/ru unknown
- 2012-03-02 UA UAA201309553A patent/UA110505C2/ru unknown
-
2013
- 2013-08-02 CO CO13184705A patent/CO6791568A2/es not_active Application Discontinuation
- 2013-08-02 CL CL2013002219A patent/CL2013002219A1/es unknown
- 2013-09-03 ZA ZA2013/06615A patent/ZA201306615B/en unknown
-
2014
- 2014-04-10 HK HK18105491.3A patent/HK1245676A1/zh unknown
-
2017
- 2017-05-15 AU AU2017203244A patent/AU2017203244B2/en active Active
-
2021
- 2021-04-12 HR HRP20210575TT patent/HRP20210575T1/hr unknown
- 2021-05-06 CY CY20211100386T patent/CY1124093T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2013002219A1 (es) | Composicion inmunogena que comprende bordetella bronchiseptica y un antigeno de pertactina aislado; y su uso para tratar o prevenir la infeccion por un patogeno respiratorio canino en un perro. | |
CO2017006580A2 (es) | Anticuerpos humanos para hemaglutinina de influenza | |
CL2016000650A1 (es) | Composicion de vacuna que comprende un antigeno y una formulacion coadyuvante, que comprende al menos el 50 % v/v de una fase oleosa, monofosforil-lipido a (mpl-a) o un analogo del mismo y un oligonucleotido inmunoestimulate; y uso de la composición de vacuna para preparar un medicamento. | |
AR092177A1 (es) | Metodos para tratar o prevenir asma administrando un antagonista de il-4r | |
CL2008000445A1 (es) | Metodo para la profilaxis y el tratamiento de una infeccion subclinica por circovirus porcino tipo 2 (pcv2) en un animal individual o un grupo de animales que comprende administrar un antigeno del pcv2; uso del antigeno pcv2 para la profilaxis de un | |
EA201501033A1 (ru) | Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний | |
AR056566A1 (es) | Vacunas y procedimientos para tratar la gripe canina | |
CL2011002639A1 (es) | Cepa bacteriana de mycoplasma bovis atenuada avirulenta; composicion inmunogenica que la comprende; y uso para fabricar un medicamento para infecciones producidas por m. bovis. | |
DK2459216T3 (da) | Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer | |
BRPI1006452A2 (pt) | vacina ou composição imunogênica que é administrada após a exposição a indivíduos com infecção latente que previne a reativação de tuberculose; método para tratar um animal, incluindo o ser humano, contra a reativação da infecção por tuberculose causada por micobactérias virulentas, uso de um antígeno selecionado do grupo | |
UY32874A (es) | Compuestos y composiciones como moduladores de la actividad de tlr | |
UA116999C2 (uk) | Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить | |
AR060565A1 (es) | Vacuna para la gripe aviaria y metodos de uso | |
AR101740A1 (es) | Terapia de combinación y composiciones | |
CL2011000877A1 (es) | Composicion inmunogena para el tratamiento y/o profilaxis de ganado contra infecciones microbiologicas porque comprende antigeno de mycoplasma bovis; metodo de coadministracion de dos o mas antigenos a un ganado bovino. | |
PH12017501370A1 (en) | Bivalent swine influenza virus vaccine | |
BR112017003462A2 (pt) | coronavírus bovino atenuado, vacina, e, método de vacinação de um bovino. | |
EA201171032A1 (ru) | Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами | |
AR056733A1 (es) | Uso de vacunas para el tratamiento / prevencion de la transmision de patogenos | |
PH12015501875A1 (en) | Acellular pertussis vaccine | |
AR056712A1 (es) | Composicion y vacuna efectiva para tratar prevenir o mejorar la inoculacion del virus de la influenza canina metodo pra generar un inmunogen del virus dela influenza equina o del virus de la influenza canina modelo de la inoculacion util para determinar la eficacia de la composicion contra el virus | |
NZ731659A (en) | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus | |
CO2022012272A2 (es) | Vacunas contra el coronavirus y métodos de uso | |
BR112016015078A2 (pt) | método para prevenir ou tratar infecção por vírus influenza a h7n9, uso do anticorpo e composição farmacêutica | |
CO6551684A2 (es) | Uso de una fuente de l3 y/o l5 como vacuna o como diagnóstico para una enfermedad parasitaria |